异常凝血酶原（PIVKA-II）是维生素K缺乏或拮抗剂-II诱导的蛋白质，可出现于维生素K缺乏或肝细胞肝癌（HCC）患者的血清中，是诊断HCC的另一个重要指标，可与AFP互为补充。 多数研究结果均表明，与经典的肝癌标志物AFP相比，DCP具有更好的临床诊断性能。 MITA等采用ELISA检测HCC患者血清DCP和AFP，结果显示，有62%（56/91）的HCC患者的DCP水平高于临界值（40 mAU/mL），而仅有47%（43/91）的HCC患者AFP水平高于临界值（20 ng/mL）。 CARR等 …

Protein induced by vitamin K absence-II (PIVKA-II) is a potential screening marker for hepatocellular carcinoma (HCC). Limited data are available about its utility in discriminating neoplastic from regenerative nodules at ultrasonography (US) evaluation in cirrhotic patients.

Apr 13, 2023 · PIVKA-II is a promising serum biomarker for the HCC diagnosis that can be used as a supplement for AFP. The combined diagnosis of the two markers greatly improved the diagnostic efficiency of HCC.

PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. Conclusion: Our recommendation is for addition of PIVKA-II to the routine panel of HCC tumour markers.

Jun 28, 2021 · 近年来，新的肝癌指标－异常凝血酶原（Pivka-II）进入我们的视野。 Pivka-II是血液凝固因子的第II因子体，在肝细胞癌中出现特异性上升。 为与AFP无关的辅助标记物，在肝细胞癌诊断及治疗效果判定中作为标记物进行检测，主要用于对以确定的肝癌患者进行动态监测以辅助判断疾病进展或治疗效果，但其浓度高低与肿瘤大小、生长、恶性程度以及分级/分期并无直接关系。 异常凝血酶原有助于判断疾病进展，异常凝血酶原阳性的患者肝内转移、包膜侵袭和血管 …

Sep 30, 2021 · Protein induced by vitamin K absence or antagonist-II (PIVKA-II), also known as des-gamma carboxyprothrombin (DCP), was first introduced as a novel HCC biomarker in 1984. 18 With the development of research over the years, PIVKA-II’s clinical significance in primary liver cancer diagnosis and management has been emphasized. 19, 20 Furthermore ...

pivka-ii（异常凝血酶原）不仅应用于早期肝癌的诊断，并且可应用于外科手术的疗效评估。外科根治术后，pivka-ii水平降低并维持低水平者，术后复发风险显著降低，虽然afp手术前后的变化也能预测手术的疗效，但pivka-ii的预测价值较afp更高 。

Background & aims: Prothrombin induced by vitamin K absence-II (PIVKA-II) is a diagnostic and surveillance marker for HCC mainly used in Asia, and has also been shown to be a predictor of microvascular invasion (MVI), a major prognostic factor in HCC. However, experience with PIVKA-II in Europe remains limited.

异常凝血酶原（PIVKA-II）是维生素K缺乏或拮抗剂-II诱导的蛋白质，可出现于维生素K缺乏或肝细胞肝癌（HCC）患者的血清中，是诊断HCC的另一个重要指标，可与AFP互为补充。 我国目前肝癌防治形势严峻，三分之二的肝癌发现时为中晚期，1年生存率仅30-40%，提高对早期肝癌的筛查和诊断率，至关重要。 有研究表明： 1、 除HCC之外肝病患者血清PIVKA-II水平轻度升高，但HCC患者血清PIVKA-II水平却显著升高；HCC患者血清中PIVKA-II阳性率为55%，与AFP无相 …

PIVKA-II was first described as a new biomarker in 1996 and has been used since the beginning of the 21st century. This pilot study represents the first study conducted in the Czech Republic related to PIVKA-II, which reflects the low incidence rate of this cancer type both in the Czech Republic and Europe as a whole.